INNOVACAP

Innova Captab Limited

Contract development and manufacturing organisation and branded generics firm

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

innovacaptab.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹1019.80
Market cap
5,837 Cr
Stock P/E
37.9
P/B
5.35
Dividend yield
0.2%
ROE (FY26)
12.9%
ROCE (FY26)
14.3%
Operating margin (FY26)
12.1%
Debt / equity (FY26)
0.32
OCF / EBITDA (FY26)
48.0%
OCF / EBITDA (3Y)
56.0%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Innova Captab makes medicines for other drug companies under contract (contract development and manufacturing, or CDMO) and sells its own branded generic medicines in India and abroad.

Company snapshot

56thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Interest coverage of 11.7x — earnings comfortably cover interest obligations.

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales283 Cr302 Cr263 Cr294 Cr318 Cr316 Cr315 Cr352 Cr380 Cr450 Cr448 Cr471 Cr
Operating expenses (approx.)242 Cr258 Cr225 Cr252 Cr268 Cr270 Cr267 Cr299 Cr329 Cr381 Cr383 Cr398 Cr
EBITDA40 Cr45 Cr38 Cr42 Cr50 Cr47 Cr48 Cr52 Cr52 Cr69 Cr65 Cr73 Cr
OPM %14.3%14.7%14.5%14.3%15.6%14.7%15.2%14.8%13.6%15.4%14.5%15.5%
Other income3 Cr2 Cr6 Cr2 Cr2 Cr4 Cr3 Cr4 Cr4 Cr2 Cr2 Cr2 Cr
Interest9 Cr7 Cr0.81 Cr0.14 Cr0.15 Cr0.17 Cr2 Cr3 Cr5 Cr4 Cr5 Cr4 Cr
Depreciation5 Cr5 Cr3 Cr5 Cr5 Cr5 Cr10 Cr11 Cr11 Cr11 Cr11 Cr12 Cr
Profit before tax30 Cr35 Cr40 Cr39 Cr47 Cr46 Cr39 Cr43 Cr39 Cr56 Cr51 Cr59 Cr
Tax %24.1%28.6%27.4%25.0%25.2%25.0%24.8%27.3%24.4%24.3%24.8%25.2%
Net profit23 Cr25 Cr29 Cr29 Cr35 Cr34 Cr30 Cr31 Cr30 Cr42 Cr38 Cr44 Cr
EPS (₹)₹4.77₹4.39₹5.02₹5.15₹6.12₹5.97₹5.17₹5.42₹5.18₹7.37₹6.65₹7.71

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales411 Cr801 Cr926 Cr1,081 Cr1,244 Cr1,630 CrSign in free for the trailing twelve months
Operating expenses (approx.)356 Cr705 Cr813 Cr927 Cr1,058 Cr1,387 CrSign in free for the trailing twelve months
EBITDA54 Cr96 Cr114 Cr154 Cr186 Cr243 CrSign in free for the trailing twelve months
OPM %13.3%12.0%12.3%14.3%15.0%14.9%Sign in free for the trailing twelve months
Other income1 Cr3 Cr9 Cr12 Cr12 Cr7 CrSign in free for the trailing twelve months
Interest4 Cr6 Cr20 Cr21 Cr2 Cr17 CrSign in free for the trailing twelve months
Depreciation6 Cr8 Cr11 Cr16 Cr25 Cr45 CrSign in free for the trailing twelve months
Profit before tax46 Cr86 Cr92 Cr130 Cr171 Cr188 CrSign in free for the trailing twelve months
Tax %25.6%25.4%26.0%27.2%25.0%25.1%Sign in free for the trailing twelve months
Net profit35 Cr64 Cr68 Cr94 Cr128 Cr141 CrSign in free for the trailing twelve months
EPS (₹)₹7.19₹13.32₹14.16₹18.66₹22.41₹24.63Sign in free for the trailing twelve months
Dividend payout %———0.0%0.0%8.1%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital12 Cr12 Cr48 Cr57 Cr57 Cr57 Cr
Reserves133 Cr197 Cr229 Cr774 Cr902 Cr1,034 Cr
Borrowings45 Cr198 Cr235 Cr245 Cr338 Cr344 Cr
Other liabilities180 Cr169 Cr193 Cr245 Cr283 Cr403 Cr
Total liabilities370 Cr575 Cr704 Cr1,321 Cr1,580 Cr1,837 Cr
Fixed assets (net)76 Cr157 Cr150 Cr340 Cr812 Cr823 Cr
CWIP7 Cr0.03 Cr22 Cr341 Cr23 Cr16 Cr
Investments0 Cr0 Cr0 Cr0 Cr0 Cr41 Cr
Loans & advances———0.44 Cr0.68 Cr0.44 Cr
Inventories91 Cr128 Cr117 Cr144 Cr208 Cr283 Cr
Trade receivables139 Cr213 Cr265 Cr288 Cr332 Cr437 Cr
Cash & bank5 Cr0.15 Cr4 Cr12 Cr16 Cr3 Cr
Other assets51 Cr78 Cr147 Cr195 Cr190 Cr233 Cr
Total assets370 Cr575 Cr704 Cr1,321 Cr1,580 Cr1,837 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity42 Cr59 Cr67 Cr146 Cr64 Cr117 Cr
Cash from investing-20 Cr-188 Cr-91 Cr-499 Cr-152 Cr-107 Cr
Cash from financing-19 Cr125 Cr27 Cr361 Cr92 Cr-22 Cr
Net cash flow3 Cr-5 Cr3 Cr8 Cr4 Cr-12 Cr
Free cash flow (OCF − Capex)23 Cr-21 Cr-11 Cr-141 Cr-109 Cr48 Cr

Ratios

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %26.5%22.5%21.8%14.0%13.4%14.3%
ROE %23.8%30.7%24.6%11.4%13.4%12.9%
Debtor days12397104979798
Inventory days11081667695103
Days payable13692899492115
Cash conversion cycle9886817910085
OCF / EBITDA %76.3%61.3%59.1%94.7%34.3%48.0%
OCF / EBITDA % (3 years)——63.4%74.8%61.0%56.0%
Debt / equity0.310.950.850.290.350.32
Current ratio1.261.291.592.181.971.87
Net debt / EBITDA0.742.062.041.511.731.40